- Trials with a EudraCT protocol (205)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
205 result(s) found for: DSM-IV Schizophrenia.
Displaying page 8 of 11.
EudraCT Number: 2015-001599-23 | Sponsor Protocol Number: SIMPET-1 | Start Date*: 2016-06-27 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||||||||||||
Full Title: In Vivo Imaging of Neuroinflammation in Simvastatin-Treated Schizophrenic Patients | ||||||||||||||||||||||||||||
Medical condition: Schizophrenia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005399-16 | Sponsor Protocol Number: ROAC2014 | Start Date*: 2014-08-05 | |||||||||||
Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL | |||||||||||||
Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients. | |||||||||||||
Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020616-11 | Sponsor Protocol Number: WN25306 | Start Date*: 2011-03-03 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt... | |||||||||||||
Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003475-13 | Sponsor Protocol Number: A1281148 | Start Date*: 2006-12-08 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT... | |||||||||||||
Medical condition: Schizophrenia and Schizoaffective Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004528-19 | Sponsor Protocol Number: I001PS0807_1 | Start Date*: 2008-01-11 |
Sponsor Name:University of Wuerzburg | ||
Full Title: Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol® | ||
Medical condition: schizophrenia (295.10, 295.20, 295.30, 295.90 according to Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-001168-39 | Sponsor Protocol Number: SNR01-NaBen | Start Date*: 2019-09-23 | |||||||||||
Sponsor Name:SyneuRx International (Taiwan) Corp | |||||||||||||
Full Title: An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on ... | |||||||||||||
Medical condition: Treatment for Schizophrenia in Adolescents | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001128-30 | Sponsor Protocol Number: BIIT001 | Start Date*: 2008-05-07 |
Sponsor Name:SE Dept. of Psychiatry and Psychotherapy | ||
Full Title: EFFICACY OF SERTINDOLE AS COMPARED TO OLANZAPINE OR RISPERIDONE ON PREATTENTIONAL AND ATTENTION-DEPENDENT FUNCTIONS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. A COGNITIVE AND FMRI STUDY. | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018963-40 | Sponsor Protocol Number: CRO1498 | Start Date*: 2011-04-14 |
Sponsor Name:Imperial College London | ||
Full Title: A multi-centre, double-blind, individually randomised, placebo-controlled, parallel arm RCT with 12-week follow-up to establish the clinical and cost effectiveness of amisulpride augmentation of cl... | ||
Medical condition: Schizophrenia that has proved unresponsive to standard treatment and a subsequent trial of clozapine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017673-38 | Sponsor Protocol Number: 2009-017673-38 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:QUALISSIMA | |||||||||||||
Full Title: Comparaison des effets de l’aripiprazole et de la rispéridone sur le profil d’activation cérébrale chez des patients schizophrènes lors de tâches émotionnelles et en référence à des sujets témoins | |||||||||||||
Medical condition: Patients schizophrènes et volontaires sains Schizophrénie (PT = LLT :10039626, SOC :10037175) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001217-42 | Sponsor Protocol Number: CN138-489 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome | |||||||||||||
Medical condition: Subjects with schizophrenia who developed metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) GR (Prematurely Ended) CZ (Completed) ES (Completed) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003466-33 | Sponsor Protocol Number: 1103-011 | Start Date*: 2013-05-17 | |||||||||||
Sponsor Name:Mental Health Services North Holland North | |||||||||||||
Full Title: Memantine Add-On Therapy to Clozapine | |||||||||||||
Medical condition: Cognitive functioning, severity of psychopathology and treatment response (positive symptoms and negative symptoms of schizophrenia), depressive symptoms, social cognition, obsessive-compulsive sy... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002694-22 | Sponsor Protocol Number: R092670PSY3002 | Start Date*: 2005-02-07 |
Sponsor Name:Janssen-Cilag International N.V | ||
Full Title: A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, ... | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) AT (Completed) SE (Completed) CZ (Completed) DK (Completed) EE (Completed) ES (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016245-26 | Sponsor Protocol Number: H8Y-MC-HBCO | Start Date*: 2010-02-02 | |||||||||||
Sponsor Name:Lilly S.A | |||||||||||||
Full Title: Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamient... | |||||||||||||
Medical condition: Esquizofrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020718-26 | Sponsor Protocol Number: WN25305 | Start Date*: 2011-01-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt... | |||||||||||||
Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004546-15 | Sponsor Protocol Number: 12-PP-12 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up | |||||||||||||
Medical condition: severe behavioral disorders in mental retardation, autistic syndromes schizophrenia psychosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005734-20 | Sponsor Protocol Number: R076477-SCA-3002 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Janssen L.P. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020470-42 | Sponsor Protocol Number: WN25308 | Start Date*: 2011-01-10 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n... | |||||||||||||
Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000343-33 | Sponsor Protocol Number: 248.641 | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investig... | |||||||||||||
Medical condition: Tourette's Syndrome (TS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020467-21 | Sponsor Protocol Number: WN25309 | Start Date*: 2010-11-23 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Estudio en fase III multicéntrico aleatorizado, de 24 semanas, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes estables c... | |||||||||||||
Medical condition: Tratamiento de los síntomas negativos en pacientes con esquizofrenia tratados con antipsicóticos Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013028-21 | Sponsor Protocol Number: ------ | Start Date*: 2009-10-16 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | |||||||||||||
Full Title: USE OF CLINICAL AND INTERMEDIATE PHENOTYPES TO ASSESS RESPONSE TO QUETIAPINE: THE ROLE OF PUTATIVE CAUSATIVE GENES | |||||||||||||
Medical condition: schizophrenia using the Structured Clinical Interview for Diagnosis (SCID) for the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV); | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
